The purpose of a new study published in Wiadomosci Lekarskie was to determine the efficacy of rosuvastatin in complex treatment of chronic obstructive pulmonary disease COPD combined with ischemic heart disease IHD . In this study 30 patients with COPD combined with IHD between 51 and 67 years of age were examined. These patients were divided into two age compatible groups 15 patients in the main group underwent regular COPD and IHD treatment along with 20 mg of rosuvastatin per night whereas the remaining 15 in the observed group did not receive rosuvastatin. It was observed that after the treatment an improvement of clinical state was found in both the groups due to decreased intensity of respiratory symptoms such as cough amount of expectoration dyspnea and increased tolerance to physical exercise as well as improvement in laboratory instrumental indices. Moreover patients of the main group had considerably lesser amount of expectoration and cough. On walking test the distance covered in 6 minutes was positively longer. Interestingly patients of the main group had decreased wheezing after treatment. Hence it was concluded that including rosuvastatin into the treatment scheme allows a decrease and stabilization of the main clinical symptoms of patients with COPD combined with IHD improving quality of life and reducing the frequency of exacerbations.